Cost-Effectiveness of PARP Inhibitors for Patients with BRCA1/2-Positive Metastatic Castration-Resistant Prostate Cancer—The Canadian Perspective
While providing survival benefits to previously progressed mCRPC patients presenting deleterious BRCA1/2 gene mutations, PARP inhibitors are not cost-effective and require major price reductions to reach local WTP thresholds.
Authors
- I Yanev (ORCID: https://orcid.org/0000-0002-2264-2683)
- Brendan L. Raizenne
- Alice Dragomir (ORCID: https://orcid.org/0000-0003-3858-3777)
- Armen Garo Aprikian
Institutions
- McGill University Health Centre (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Polytechnique Montréal (CA)
- McGill University (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Cancers
- Published
- 2024-12-26
- DOI
- https://doi.org/10.3390/cancers17010040
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.57